Biopharmaceuticals Contract Manufacturing Market Outlook to 2027 - WuXi Biologics, General Electric, Samsung Biologics, Merck KGaA

Publisher: The Insight Partners

The Biosimilars Segment byProductis expectedtogrowatA Fast Pace overthe Forecast Period

According to The Insight Partners market research study of ‘Biopharmaceuticals Contract Manufacturing Market to 2027 – Global Analysis and Forecasts by Product, and Service.’ The global biopharmaceuticals contract manufacturingmarket is expected to reach US$ 25,497.26Mn in 2027 from 13,727.13Mn in 2019. The market is estimated to grow with a CAGR of 8.2% from 2020-2027. The report provides trends prevailing in the global biopharmaceuticals contract manufacturing marketand the factors driving market along with those that act as hindrances.

The global biopharmaceuticals contract manufacturing market, based on the product, is segmented into biologics and biosimilars.The biologicssegment held the largest share of the market in 2019. Whereas, the biosimilar segment is estimated to register the highest CAGR in the market during the forecast period owing to increasing demand of biologics, increasing research activities in niche markets and growing biologics pipeline. Moreover, many big pharmaceutical companies prefer contract manufacturers to scale up their production and manage operating expenses.

Get Sample PDF Copy at https://www.theinsightpartners.com/sample/TIPRE00005512/                

Market Insights

Increasing Demand of Biologics

The contract manufacturing market for biologics is growing at an unprecedented rate owing to increasing biologics pipeline, manufacturing complexity, and companies shifting their focus towards core activities. Presently, many pharmaceutical and biotechnology companies outsource varied services from early-stage drug development to commercial-scale manufacturing. The outsourcing is required to expedite research and development, speed up market entry, give access to novel technologies, regulatory expertise, and reduces risks at a competitive cost. Complexities in biologics development and production and increasingly stringent quality standards have driven drug manufactures to prefer contract manufacturer services. Moreover, many companies are opting CMOs services to speed up the development process and lower production costs. For instance, in 2019, Dyadic International, Inc. agreed with Luina Bio Pty Ltd for the development and commercialization of its specific targeted antigen and biological products.

Product Insights

Based on product, biopharmaceuticals contract manufacturing market is segmented into biosimilar and biologics. The biologics segment held the largest share of the market in 2019 owing to increasing demand for biologics, increasing research, and development activities to develop new drugs for chronic indications in the forecast period. The market for biosimilar is expected to register the highest CAGR in the market during the forecast period due to patent expiration of blockbuster drugs and increasing pipeline.

Service Insights

The biopharmaceuticals contract manufacturing market, by service, is segmented into development process, final dosage operations, analytical and quality control and final packaging. In 2019, the development process accounted for the largest market share in the global biopharmaceuticals contract manufacturing market owing to cutting edge technologies, risk becomes higher for small drug manufactures. However, analytical and quality control services are expected to grow at a significant CAGR in the forecast period owing to stringent regulatory regulation and complex manufacturing requirements of biologics.

Strategic Insights

Product launches and expansion strategy is commonly adopted by companies to expand their footprint worldwide and meet the growing demand. This strategy is most commonly adopted by the market players in order to expand its product portfolio.

The market players operating in the biopharmaceuticals contract manufacturing market adopted the strategy of product innovation to cater to changing customer demand across the world, which also permits the players to maintain their brand name globally.

The biopharmaceuticals contract manufacturing market is expected to grow, owing to the increasing outsourcing by pharmaceutical companies, growing biologics pipeline and growth in emerging markets. However, increasing competition among contract manufacturers is expected to restraint the growth of the market during the forecast years.

Leading companies operating in the biopharmaceuticals contract manufacturing marketare Lonza Group AG, Boehringer Ingelheim International GmbH, Inno Biologics Ventures Sdn Bhd,Thermo Fisher Scientific, AbbVie Inc., and WuXi Biologics, General Electric, Samsung Biologics, Merck KGaA, Ajinomoto Co., Inc. among others. 

Purchase this Premium Report at https://www.theinsightpartners.com/buy/TIPRE00005512/     

Contact Us

Contact Person: Content Team

Phone: +1-646-491-9876

Email Id: sales@theinsightpartners.com